Form 4: Lexicon Pharmaceuticals CEO Lonnel Coats Reports Stock Transactions
SEC Form 4 Filing
CEO Lonnel Coats reports the vesting and conversion of restricted stock units into common stock, along with a transaction to cover tax obligations.
Summary
- On February 28, 2024, Lonnel Coats, CEO of Lexicon Pharmaceuticals, engaged in transactions involving restricted stock units and common stock.
- Coats converted 33,333, 91,364, and 120,383 restricted stock units into an equivalent number of common stock shares.
- A portion of the issued shares, totaling 61,371, were withheld by Lexicon Pharmaceuticals to satisfy tax obligations at a price of $2.62 per share.
- Following these transactions, Coats directly owns 1,098,068 shares of Lexicon Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, which is neutral in sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It is standard practice for executives to receive and vest stock options and restricted stock units as part of their compensation packages.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the number of outstanding shares, but the effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 02/28/2024 | Date of stock transactions and vesting of restricted stock units. |
| 02/29/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.